When Will AbCellera Biologics Inc (NASDAQ: ABCL) Be A Good Investment?

In the latest trading session, 1.77 million AbCellera Biologics Inc (NASDAQ:ABCL) shares changed hands as the company’s beta touched 0.42. With the company’s most recent per share price at $3.08 changed hands at -$0.09 or -3.00% at last look, the market valuation stands at $908.25M. ABCL’s current price is a discount, trading about -77.27% off its 52-week high of $5.46. The share price had its 52-week low at $2.34, which suggests the last value was 24.03% up since then. When we look at AbCellera Biologics Inc’s average trading volume, we note the 10-day average is 4.11 million shares, with the 3-month average coming to 3.11 million.

Analysts gave the AbCellera Biologics Inc (ABCL) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.22. If we narrow down to specifics, the data shows that 0 out of 9 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 2 recommended ABCL as a Hold, 7 felt it is a Buy and 0 rated the stock as Underweight. AbCellera Biologics Inc’s EPS for the current quarter is expected to be -0.15.

AbCellera Biologics Inc (NASDAQ:ABCL) trade information

Instantly ABCL was in red as seen in intraday trades today. With action -8.48%, the performance over the past five days has been red. The company’s shares are showing year-to-date upside of 4.95%, with the 5-day performance at -8.48% in the red. However, in the 30-day time frame, AbCellera Biologics Inc (NASDAQ:ABCL) is 4.95% up. Looking at the short shares, we see there were 17.26 million shares sold at short interest cover period of 5.37 days.

The consensus price target for the stock as assigned by Wall Street analysts is 5, meaning bulls need an upside of 38.4% from its recent market value. According to analyst projections, ABCL’s forecast low is 5 with 5 as the target high. To hit the forecast high, the stock’s price needs a -62.34% plunge from its current level, while the stock would need to soar -62.34% for it to hit the projected low.

AbCellera Biologics Inc (ABCL) estimates and forecasts

Data shows that the AbCellera Biologics Inc share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot 0.82% over the past 6 months, a -15.69% in annual growth rate that is considerably lower than the industry average of 15.90%. Year-over-year growth is forecast to reach -16.95% down from the last financial year.

Consensus estimates given by 10 financial analysts project the company’s revenue in the current quarter to hit an average of 7.58M. 2 analysts are of the opinion that AbCellera Biologics Inc’s revenue for the current quarter will be 13.97M. The company’s revenue for the corresponding quarters a year ago was 9.2M and 9.95M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -17.62%. The estimates for the next quarter sales put growth at 40.33%.

The 2025 estimates are for AbCellera Biologics Inc earnings to decrease by -15.13%, but the outlook for the next 5-year period is at 1.59% per year.

ABCL Dividends

AbCellera Biologics Inc is expected to release its next quarterly earnings report in March.

AbCellera Biologics Inc (NASDAQ:ABCL)’s Major holders

If we look at who the major shareholders are, we find that insiders hold 27.93% of AbCellera Biologics Inc shares while 39.36% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 54.62%. There are 39.36% institutions holding the AbCellera Biologics Inc stock share, with BAKER BROS. ADVISORS LP the top institutional holder. As of 2024-06-30, the company held 9.4033% of the shares, roughly 27.53 million ABCL shares worth $81.48 million.

BAILLIE GIFFORD & CO holds the second largest percentage of outstanding shares, with 7.4852% or 21.91 million shares worth $64.86 million as of 2024-06-30.

Among Mutual Funds, the top two as of Nov 30, 2024 were iShares Biotechnology ETF and Vanguard Valley Forge Fds-Baillie Gifford Global Pos Impact Stock Fd. With 1.42 shares estimated at $4.38 million under it, the former controlled 0.48% of total outstanding shares. On the other hand, Vanguard Valley Forge Fds-Baillie Gifford Global Pos Impact Stock Fd held about 0.15% of the shares, roughly 454.44 shares worth around $1.41 million.